<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346215</url>
  </required_header>
  <id_info>
    <org_study_id>HEPBER0211</org_study_id>
    <nct_id>NCT01346215</nct_id>
  </id_info>
  <brief_title>Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure</brief_title>
  <official_title>Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratório Químico Farmacêutico Bergamo Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratório Químico Farmacêutico Bergamo Ltda.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate clinical non-inferiority, pharmacodynamic effect&#xD;
      and safety of Actparin® (heparin sodium - Laboratório Químico Farmacêutico Bergamo Ltd.)&#xD;
      compared to Heparin Sodium (APP Pharmaceuticals) in patients with renal failure under&#xD;
      hemodialysis treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness in prevention of clotting in the extracorporeal circuit during hemodialysis</measure>
    <time_frame>4 weeks (12 consecutive sessions)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity of heparin observed through aPTT marker</measure>
    <time_frame>4 weeks (sessions 1, 6 and 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety in use of heparin by monitoring adverse events</measure>
    <time_frame>5 weeks (12 consecutive sessions + 1 post treatment session)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Actparin® - Laboratorio Bergamo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin sodium - APP Pharmaceuticals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heparin sodium</intervention_name>
    <description>5000 UI/mL</description>
    <arm_group_label>Actparin® - Laboratorio Bergamo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heparin sodium</intervention_name>
    <description>5000 UI/mL</description>
    <arm_group_label>Heparin sodium - APP Pharmaceuticals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients research that agree to participate in the study and sign the informed consent&#xD;
             form;&#xD;
&#xD;
          -  Patients aged over 18 years, both sexes, regardless of color or social class;&#xD;
&#xD;
          -  Patients with impaired renal function in chronic hemodialysis schedule of at least 3&#xD;
             times a week and giving the use of heparin in the prophylaxis of thrombosis in the&#xD;
             system;&#xD;
&#xD;
          -  Patients with laboratory results within specified acceptance criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are taking part or took part in another clinical investigational study&#xD;
             within 12 months;&#xD;
&#xD;
          -  Hypersensitivity to heparin sodium and/or benzyl alcohol;&#xD;
&#xD;
          -  History of active hemorrhage with alteration of blood coagulation, such as genetic&#xD;
             disorders of coagulation system;&#xD;
&#xD;
          -  History of disease that could aggravate or terminate the clinical manifestations, such&#xD;
             as active peptic or gastric ulcer;&#xD;
&#xD;
          -  Severe liver disease;&#xD;
&#xD;
          -  Patients in cancer treatment;&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  Use of glucocorticoids over physiological dose;&#xD;
&#xD;
          -  Use of other anticoagulants;&#xD;
&#xD;
          -  Patients undergoing any surgery performed less than 15 days;&#xD;
&#xD;
          -  History of non response or exacerbated response to heparin sodium;&#xD;
&#xD;
          -  Patients who do not adapt to 150 UI/kg dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo A. C. Orlandi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Nefrologia de Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo A. C. Orlandi, Dr.</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Nefrologia de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcelo Orlandi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>MedlinePlus</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/bloodthinners.html</url>
    <description>Blood thinners</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/dialysis.html</url>
    <description>Dialysis</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/kidneyfailure.html</url>
    <description>Kidney failure</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Drug Information</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Heparin</url>
    <description>Heparin</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <last_update_submitted>April 29, 2011</last_update_submitted>
  <last_update_submitted_qc>April 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marcelo A. C. Orlandi</name_title>
    <organization>Instituto de Nefrologia de Campinas</organization>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>renal insufficiency, chronic</keyword>
  <keyword>extracorporeal dialysis</keyword>
  <keyword>fibrinolytic agents</keyword>
  <keyword>anticoagulants</keyword>
  <keyword>aPTT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

